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Abstract: Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) supplementation in the
cardiovascular field is effective if a certain Omega-3 index (O3I) is achieved or the daily n-3 LCPUFA
dose is high enough. Whether this applies to studies on cognition in children and adolescents is
unclear. The aims of the current review were to investigate whether: (1) a certain O3I level and (2) a
minimum daily n-3 LCPUFA dose are required to improve cognition in 4–25 year olds. Web of Science
and PubMed were searched. Inclusion criteria: placebo controlled randomized controlled trial;
participants 4–25 years; supplementation with docosahexaenoic acid (DHA) and/or eicosapentaenoic
acid (EPA); assessing cognition; in English and ≥10 participants per treatment arm. Thirty-three
studies were included, 21 in typically developing participants, 12 in those with a disorder. A positive
effect on cognitive measures was more likely in studies with an increase in O3I to >6%. Half of the
studies in typically developing children with daily supplementation dose ≥450 mg DHA + EPA
showed improved cognition. For children with a disorder no cut-off value was found. In conclusion,
daily supplementation of ≥450 mg DHA + EPA per day and an increase in the O3I to >6% makes it
more likely to show efficacy on cognition in children and adolescents.
Keywords: adolescents; children; long-chain polyunsaturated fatty acid; cognition; Omega-3 Index
1. Introduction
Numerous studies have investigated the influence of omega-3 long-chain polyunsaturated fatty
acids (n-3 LCPUFA) on an array of outcomes such as cardiovascular health, depression, attention deficit
(hyperactivity) disorder, autism spectrum disorder, pregnancy outcomes, cognition and cognitive
development [1–6]. The LCPUFA such as docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid
(AA, 20:4n-6) are important constituents of the brain. Moreover, DHA, AA and eicosapentaenoic
acid (EPA, 20:5n-3) are involved in bodily and brain processes such as neurite growth, membrane
fluidity, blood–brain barrier integrity and inflammation [7–9]. The suggested roles of LCPUFA in brain
development and functioning have led to a large number of observational studies and supplementation
trials in which the relationship between LCPUFA and cognition in children and adolescents was
investigated; the results of which were mixed. Some studies show positive effects of supplementation,
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while others show neutral effects. Most of these studies have been summarized in a multitude of
reviews, for example [5,10–19], yet the conclusions of these reviews are not consistent. Some conclude
that there is evidence for an effect of n-3 LCPUFA on cognition [5,10,12,14], others conclude that
there is only proof for specific subgroups of participants (i.e., infants, elderly, or those with a low n-3
LCPUFA status) [16–18], and some conclude that there is no effect or results are too mixed to draw
conclusions [11,13,15,19]. However, the studies included in these reviews are heterogeneous in their
design, various doses of LCPUFA supplements were used, and the composition of the supplements
varied greatly. Therefore, it remains uncertain whether n-3 LCPUFA supplementation can positively
influence cognition and whether the effectiveness could be related to the dose used or the circulating
level of n-3 LCPUFA in the body, represented by the Omega-3 Index (O3I).
In the area of cardiovascular disease, it has been suggested that recent neutral results in LCPUFA
supplementation trials could be due to too low n-3 LCPUFA supplementation doses and/or not achieving
the cardio-protective O3I range of 8–11% [20]. The O3I is defined as EPA plus DHA in erythrocytes and is
based on a standardized analytical method [21]. A target range for the O3I of 8–11% has been suggested as
this range is associated with the lowest mortality risk in coronary heart disease [21]. Some have suggested
that such a target range could also exist for mental health diseases [22].
In a review of studies investigating the effect of n-3 LCPUFA on death from cardiovascular disease,
only trials in which the daily dose of DHA was at least 500 mg showed a reduction in cardiovascular
mortality [20]. In line with this finding, in the meta-analysis of Emery et al., an effect of n-3 LCPUFA
supplementation on cognition (i.e., on the domains recall and recognition long-term memory) was only
evident when studies with a dose of less than 400 mg DHA + EPA were excluded from the analyses [23].
This indicates that a n-3 LCPUFA supplementation dose above 400 mg DHA + EPA might be effective
in improving cognition. Nonetheless, Emery et al. were not able to show dose trends for DHA nor
EPA for the outcome measures short term memory, attention and inhibition (i.e., a higher dose of
EPA or DHA was not related to higher score on short term memory, attention and inhibition tests).
However, do note that Emery et al. combined the results of multiple different cognitive tests into one
outcome measure. For example, for the outcome measure inhibition results from the KiTap, Stroop
test, Matching Familiar Figures tasks, Connors performance test, Test of Variables of Attention, Arrow
Flanker Test and Amsterdam Neuropsychological Tasks were combined. Combining such diverse tests
can be problematic as even though the tests seem similar, the underlying constructs can be somewhat
different and operational differences can also be present [24].
Taking into account the findings with regard to O3I range in cardiovascular health and the limitations
of n-3 LCPUFA dose in research on cognition, the question was raised whether the mixed results in
n-3 LCPUFA supplementation studies for cognition could be attributed to the O3I (not reported in the
Emery review) or the n-3 LCPUFA supplementation dose. Therefore, a systematic literature review
was undertaken with the aim (1) to investigate what O3I is needed to improve cognition, and (2) to
investigate whether the daily dose of DHA/EPA plays a role in the effect of n-3 LCPUFA supplementation
on cognition.
The focus of the current review is on n-3 LCPUFA supplementation trials in children and adolescents,
as the brain develops up to age 25 years and it is to be expected that effects of n-3 LCPUFA supplementation
on cognition are therefore more pronounced in children and adolescents than in adults [25].
2. Materials and Methods
A systematic literature review was conducted. The review protocol was not registered beforehand.
Web of Science and PubMed were searched up to the 3th of July 2019 with the following search
terms: ‘LCPUFA’, ‘EPA’, ‘DHA’, ‘Omega-3′, in combination with ‘cogniti*, and ‘child*, ‘adolescen*’,
‘toddler’ (for exact search strategy see Appendix A). No date restrictions were applied. Earlier reviews
and reviews located in the literature search on LCPUFA and cognition were checked for additional
manuscripts to include. The reference lists of included manuscripts were checked for additional
manuscripts. Moreover the ‘cited by’ function in Web of Science, or PubMed if the manuscript was not
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available in Web of Science, was utilized to check whether any of the manuscripts citing the included
manuscripts were suitable for inclusion themselves.
Studies were eligible for inclusion if (1) the average age of participants was between 4 and 25 years
old; (2) participants (i.e., the child or adolescent) received supplementation with DHA and/or EPA;
(3) the study included a measure of cognition; (4) the study was a randomized placebo controlled trial
(RCT); (5) cross-over studies had a wash-out period of at least four months as this is the duration which
is needed for erythrocyte concentrations to return to pre-supplementation levels [24]; (6) the study
included a minimum of 10 participants per treatment arm; (7) the study was published in English.
All manuscripts were scanned by the first author and the following information was extracted:
information on study population, supplementation (placebo and active), supplementation duration,
adherence percentage, test used to assess cognition, LCPUFA measurement method if included
and outcomes.
To compare studies that included blood values, the measured fatty concentrations, if reported,
were converted to the O3I with the formulae as suggested by Stark and colleagues [25], called the O3I
equivalence from here onwards.
3. Results
3.1. Included Studies
The database search yielded 890 manuscripts, and checking of relevant reviews yielded 19
additional manuscripts, after removal of duplicates 665 manuscripts remained (for flow chart see
Figure 1). After screening based on title and/or abstract 549 manuscripts were excluded due to not
meeting the inclusion criteria. Of 116 manuscripts the whole text was screened, 83 manuscripts
were excluded based on the whole text (for reasons see Figure 1). In the end 33 placebo controlled
randomized controlled trials (RCTs) investigating the influence of LCPUFA supplementation on
cognition were included in the current review. In 21 of these studies, typically developing children and
adolescents were included, in 12 the focus was on children and adolescents with a disorder or disease.
Of the 12 studies in which the focus was on a disorder or a disease, the vast majority, namely 11 studies,
focused on children or adolescents with attention deficit hyperactivity disorder (ADHD). In one study
the focus was on children with phenylketonuria (PKU). The majority of studies was either in children
(<12 years, n = 24) or late adolescents (20–25 years of age, n = 8), very few studies focused on early or
middle adolescence (12–20 years of age, n = 1). The duration of the studies varied from four weeks up
to 52 weeks. An overview of the included studies including typically developing participants can be
found in Table 1. For an overview of studies including participants with a disorder/disease see Table 2.
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Figure 1. Flow-chart of the search strategy, adapted from [26]. EPA = eicosapentaenoic acid, DHA =
docosahexaenoic acid.
Nutrients 2020, 12, 3115 5 of 25
Table 1. Overview of studies supplementing children and adolescents with long chain polyunsaturated fatty acids (LCPUFA) and including a cognitive measure as
outcome measure.
Author, n 1
Mean Age in Years
(SD) and Any
Specifics
DHA, EPA
Dosage Per day
Active Group
Other Constituents Active As
Specified in Manuscript
Placebo as Specified in
Manuscript
Duration
(in Weeks) Cognitive Tests Adherence Effect on Cognition?
Antypa
n 54
[27]
A: 22.2
P: 22.6
250 mg DHA,
1740 mg EPA, 310 mg other n-3 PUFA Olive oil 4
Affective Go/No-Go task,
attentional Go/No-Go task, 15
word test, decision-making
(gambling) task.
OS
Y, in gains only trials of
gambling task the n-3 group
showed sig. more risk-seeking
decision-making behavior
than the placebo group.
Baumgartner
n 321
[28]
6–11
iron deficient
240 mg DHA
46 mg EPA 1,3 28.6 mg iron sulfate
2,3 Medium chain
triglycerides 3 15
The Atlantis test, Atlantis
Delayed test, The Hand
Movement test, the Triangles
test, The Hopkins Verbal
Learning Test
95.4% N
Benton
n 305
[29]
21.8 400 mg DHA
10:0 5 mg, 12:0 38 mg, 14:0
121 mg, 16:0 78 mg, 18:0 10 mg,
18:1 312 mg, 18:2 15 mg,
22:0 3 mg
Maize/soya oil: 16:0
110 mg, 18:0 30 mg, 18:1
233 mg, 18: 2 567 mg, 18:5
41 mg, 20:0 4 mg, 20:1
3 mg, 22:0 2 mg
7.1
Recall of word list (immediate
and delayed), recall of capitals,
reaction time test, rapid
information processing task
NR
Y, those taking DHA sig.
forgot more than the placebo
group on the recall of word
list after 50 days.
Dalton
n 183
[30]
7–9 some
underweight,
wasted or stunted
127.3 mg DHA,
54.6 mg EPA 4,5
222.55 mg ALA, 1041.2 mg LA,
15.4 mg AA 6
55.8 mg ALA, 9.8 mg EPA,
23.7 mg DHA, 1668.2 mg
LA, 4.5 mg AA 7
14.9 Hopkins Verbal Learning Test A: 94.8%P: 94.5%
Y, sig. intervention effect for
recall 1 and recall 3,
recognition and
discrimination index score
Guzman
n 34
[31]
23.58 female elite
soccer players 3500 g DHA - Olive oil 4 Multiple reaction times NR
Y, those taking DHA showed
sig. improvement in complex
reaction time and complex
reaction efficiency
Hamazaki
n 42
[32]
Two groups:
(1) 19–20
(2) 22
1500–1800 mg
DHA,
200–240 mg EPA
dependent on
bodyweight
palmitic acid 270–324 mg, oleic
acid 219–263 mg, AA 99–119 mg,
palmitoleic acid 96–115 mg,
stearic acid and others 69–83 mg
Soybean oil + partly
deodorized fish oil: LA
1623–1948 mg, oleic acid
669–803 mg, palmitic acid
324–389 mg, ALA
204–245 mg, stearic acid
111–133 mg, DHA and
others 15–18 mg
12
Adapted Stroop test,
dementia-detecting test (to
assess higher functions of brain)
NR N
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Table 1. Cont.
Author, n 1
Mean Age in Years
(SD) and Any
Specifics
DHA, EPA
Dosage Per day
Active Group
Other Constituents Active As
Specified in Manuscript
Placebo as Specified in
Manuscript
Duration
(in Weeks) Cognitive Tests Adherence Effect on Cognition?
Jackson
n 140
[33]
DHA rich group
21.96 (0.54), EPA
rich group 22.74
(0.61) P: 21.94 (0.50)
I: DHA rich
group: 450 mg
DHA, 90 mg
EPA
II: EPA rich
group: 300 mg
EPA, 200 mg
DHA
I: NS
II: NS 1 g olive oil 12
Immediate Word Recall, Simple
RT, Choice RT, Four Choice RT,
Stroop Task, Verbal Fluency,
Alphabetic Working Memory,
Corsi Block Task, Three Block
Task, Telephone Number
Working Memory Task, Delay
Word Recall, Delayed Word
Recognition, Delayed Picture
Recognition, Names-To-Faces
Recall, Cognitive Demand
Battery (Serial 3 Subtractions,
Serial 7 Subtractions, Rapid
Visual Information Processing).
DHA: 91%
EPA: 90%
P: 92%
Y, DHA group had sig faster
reaction time on Stroop Task
compared to placebo group.
Both DHA and EPA group
matched sig. fewer items on
the Names-To-Faces-task than
the placebo group.
Jackson
n 64
[34]
20.58
1 g fish oil (FO)
group: 450 mg
DHA, 90 mg
EPA, oil. 2 g FO
group: 900 mg
DHA, 180 mg
EPA,
1 g FO: 1 g olive
2 g FO: NS 2 g olive oil 12
Corsi blocks task, Numeric
Working Memory, 3-Back Task,
Simple Reaction time, Choice
Reaction Time, Four Choice
Reaction Time, Stroop Task,
Rapid Visual Information
Processing Task, Serial 7
Subtractions while near-infra
red spectroscopy was executed.
1 g: 91%
2 g: 92%
P: 96%
Y, sig. treatment effect on
reaction time for Choice
Reaction Time task, reaction
time in both treatment groups
faster. Sig. effect of treatment
on Rapid Visual Information
Processing Task, reaction time
sig faster in 2 g FO group
compared to placebo.
Karr
n 41
[35]
FO: 19.9 (1.8)
P: 20.4 (1.6)
480 mg DHA,
720 mg EPA NS 1 g coconut oil 4
Rey Auditory Verbal Learning
Test, Stroop Color and Word
Test and Trail Making Test
99%
Y, interaction condition x test
moment sign. for Rey
auditory Verbal Learning Test
stage 6, stage 7 and summary
7–5 (FO improved from
baseline, placebo not) but
main effect cognition not sign.
Placebo condition improved
sig. over FO group on Trial
Making Test.
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Table 1. Cont.
Author, n 1
Mean Age in Years
(SD) and Any
Specifics
DHA, EPA
Dosage Per day
Active Group
Other Constituents Active As
Specified in Manuscript
Placebo as Specified in
Manuscript
Duration
(in Weeks) Cognitive Tests Adherence Effect on Cognition?
Kennedy
n 90
[36]
10–12
Low dose:
400 mg DHA,
8 mg EPA
High dose:
1000 mg DHA,
20 mg EPA
Low dose: 2092 mg vegetable oil
High dose: 1480 mg vegetable
oil 8
2.5 g vegetable oil
containing 75 mg ALA
and 1250 mg LA
8
Internet Battery (Word
Presentation, Picture
Presentation, Arrow Reaction
Time Test, Arrow Flanker Test,
Paired Associate Learning,
Sentence Verification, Delayed
Word Recognition, Delayed
Picture Recognition) and
Cognitive Drug Research
Battery (Picture Presentation,
Word Presentation/Immediate
Word Recall, Simple RT, Digit
Vigilance Task: Choice RT,
Spatial Working Memory,
Numeric Working Memory,
Delayed Word Recall, Delayed
Word Recognition, Delayed
Picture Recognition
>80%
N, sig. main treatment effect
on speed of Word Recognition
of the Cognitive Drug
Research Battery. Post-hoc
analysis: the low dose group
was sig. faster than the
placebo group. However,
the high dose group was sig.
slower than placebo group.
Kirby
n 348
[37]
8–10 400 mg DHA,56 mg EPA,
64 mg other n-3 fatty acids,
vitamin A 800 mg RE, vitamin C
60 mg, vitamin D 5 mg,
and vitamin E 3 mg
Olive oil 16
Working Memory Test Battery
for Children (digit recall, block
recall and backward digit recall),
TEA-Ch (Creature Counting),
Matching Familiar Figures Task
OS
Y, in intention to treat analysis
no sig. effects. In per protocol
analysis PUFA group had
higher number of first correct
responses on matching
familiar figures task in
comparison to baseline,
the change for placebo group
was not sig.
Long
n 202
[38]
20.9 672 mg DHA,93.3 mg EPA 9
14:0 4.5 mg, 16:0 13.8 mg, 16:1
5.4 mg, 17:0 3 mg, 18:0 39.3 mg,
18:1 70.2 mg, 18:0 12.6 mg, 18:2
10.2 mg, 18:3 4.2 mg, 18:4 5.1 mg,
20:0 8.4 mg, 20:1 34.8 mg, 20:2
(n-9) 5.4 mg, 20:3 (n-6) 2.7 mg,
20:4 (n-6) 27.9 mg, 20:3 (n-3)
3.3 mg, 20:4 (n-3) 8.4 mg, 22:0
(n-3) 5.1 mg, 22:1 (n-11) 27.9 mg,
22:1 (n-9) 6.3 mg, 22:4 (n-6) 6 mg,
22:5 (n-6) 50.7 mg, 22:5 (n-3)
35.7 mg, 24:0 4.5 mg, 24:1
20.4 mg, minor components 4.9%,
alpha tocopheryl acetate
(2.25 mg), and mixed tocopherols
(4.5 mg). multi vitamin and
mineral supplement
14:0 9.0 mg, 16:0 392.1 mg,
16:1 2.1 mg, 18:0 50.1 mg,
18:1 562.5 mg, 18:1 (n-7)
16.5 mg, 18:2 289.5 mg,
18:3 29.1 mg, 20:0 5.4 mg,
20:1 5.4 mg, 22:0 (n-3)
3.3 mg, 22:1 1.5 mg, 24:0
1.5 mg, minor components
(0.4%), alpha tocopheryl
acetate (2.28 mg),
and mixed tocopherols
(4.5 mg)
12 Go Stop Impulsivity Paradigm NR
Y, only for participants with
high impulsivity at baseline:
the % of inhibited
responses was sig. greater if
they had consumed DHA
rather than a placebo.
For participants with low
impulsivity no effect of
supplementation was shown.
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Table 1. Cont.
Author, n 1
Mean Age in Years
(SD) and Any
Specifics
DHA, EPA
Dosage Per day
Active Group
Other Constituents Active As
Specified in Manuscript
Placebo as Specified in
Manuscript
Duration
(in Weeks) Cognitive Tests Adherence Effect on Cognition?
McNamara
n 38
[39]
8–10
Low dose:
400 mg DHA
High dose:
1200 mg DHA,
Low dose: 2 g corn oil
High dose: - 3 g corn oil 8
The identical-pairs version of
the Continuous Performance
task (CPT-IP).
NR N
Montgomery
n 376
[40]
7–9
underperforming
on reading
600 mg DHA
22.5 mg EPA
14:0 72.4 mg, 16:0 222 mg, 18:0
14.5 mg, 18:1 n-9 242.9 mg, 18:2
n-6 16.1 mg, 22:5 n-6 252.5 mg
1500 mg corn/soy bean oil 16 Recall of digits Forward andRecall of Digits Backwards 75% N
Muthayya
n 598
[41]
6–10 marginally
nourished
High n-3: 86 mg
DHA 10,11
High n-3: 800 mg ALA + high or
low micronutrient 12,13
Low n-3: 120 mg ALA +
high or low
micronutrient 13,14
52
Kaufman Assessment Battery
for Children (pattern reasoning,
triangles, rover, number recall,
word order and Atlantis),
Wechsler Intelligence Scales for
Children (picture arrangement
and coding), Rey Auditory
Verbal Learning test
(auditory-verbal learning test),
Neuropsychological
Assessment Tool
(verbal fluency) and
number cancellation
70% N
Osendarp
n 780
[42]
6–10
Some marginally
nourished
88 mg DHA
22 mg EPA 15,16 Multivitamin
17 Base powder 52
Digits Backwards, Visual
Attention 2, Coding, Block
Design, Fluency Structured and
Random, Rey Auditory Verbal
Learning Test.
73–87% N
Parletta
n 408
[43]
3–13 18
174 mg DHA
558 mg EPA 60 mg GLA, 10.8 mg vitamin E
Palm oil + fraction of fish
oil 28.6 Draw-A-Person
Y, sig. treatment by group
interaction
whereby the treatment group
improved
compared to placebo.
Portillo-Reyes
n 55
[44]
8–12
Malnourished
180 mg DHA
270 mg EPA Not reported Soy bean oil 12
Symbol Search, Embedded
Figures Test, Visual Closure,
Block Design, TMT A, Letter
Cancellation, Rey Complex
Figure, Word List, Semantic
Fluency, Matrix Reasoning,
Letter-Number Sequencing,
Stroop Color and Word test,
TMT-B: Shifting.
NR
Y, only the treatment group
improved sig. in
Symbol Search, Embedded
Figures, Visual
Closure, Block Design,
Stroop-Color, Stroop
Color-Word and
Matrix Reasoning.
Richardson
n 362
[45]
7–9
underperforming
on reading
600 mg DHA NS 1500 mg corn/soy bean oil 16 Recall of Digits Forward andRecall of Digits Backwards 75%
Y, post intervention score for
Recall of
Digits Forwards sig. higher in
active treatment group.
Nutrients 2020, 12, 3115 9 of 25
Table 1. Cont.
Author, n 1
Mean Age in Years
(SD) and Any
Specifics
DHA, EPA
Dosage Per day
Active Group
Other Constituents Active As
Specified in Manuscript
Placebo as Specified in
Manuscript
Duration
(in Weeks) Cognitive Tests Adherence Effect on Cognition?
Ryan
n 202
[46]
4 400 mg DHA high-oleic sunflower oil 16
Leiter-R Test of Sustained
Attention, Day-Night Stroop
Test, and Conners’ Kiddie
Continuous Performance Test,
Peabody Picture
Vocabulary Test.
Nearly 100% N
Van der Wurff
n 267
[47]
13–15 280 mg DHA,520 mg EPA NS
Capsules with a fatty acid
profile comparable to the
fatty acid composition of
the average European diet:
mix of olive
oil, corn oil, palm oil and
medium chain
triglycerides: (16:0 26%,
18:0 4.6%, 18: 1–9 35.8%,
18:2–6 16.7%, 18:3–32.1%,
20:4–6 0% and other
compounds 14.8%)
52
Letter Digit Substitution Task,
Concept Shifting Task, Digit
Span Forwards and Backwards,
D2 test of Attention.
OS N
A= active, AA = arachidonic acid ALA = α-Linolenic acid, DHA = docosahexaenoic acid, EPA = eicosapentaenoic acid, GLA = Gamma-linolenic acid, HVLT = Hopkins Verbal Learning test,
LA = linoleic acid, MFFT = Matching Familiar Figures Task, n-3 PUFA = n-3 polyunsaturated fatty acids, N = no, NR, not reported, NS= not specified, OS = otherwise specified, P = placebo, RT
= reaction time, TMT-B = Trail Making Task part b, Y = yes. • Note that in some studies also other measures were included such as academic achievement tests (spelling, reading, math), mood
measures and more, these are not reported here. 1 Recalculated, participants received 420 mg DHA and 80 mg EPA per day four days a week, 2 Recalculated participants received 50 mg per day
four days a week 3 The study was a 2 × 2 factorial design, participants received DHA + EPA+ iron, or DHA + EPA + placebo, or placebo + iron, or placebo + placebo, 4 The children received
the supplementation in the form of buttery spread which was spread over two slices of bread. 5Recalculated, participants received 191.7 mg DHA and 82.2 mg EPA per day approximately 4.65
days per week, 104days in a 6 months period. 6Recalculated participants received 335 mg ALA, 1567.36 mg LA and 23.25 mg AA per day approximately 4.65 days per week, 104 days in a 6
months period. 7 Recalculated participants received 84 mg ALA, 14.8 mg EPA, 35.6 mg DHA, 2511.3 mg LA and 6.8 mg AA per day approximately 4.65 days per week, 104 days in a 6 months
period. 8 The amount of LA and ALA in the placebo vegetable oil was specified, this was not the case for the vegetable oil in the active supplement, the low dose group consumed 45 mg ALA
and 750 mg LA from the placebo capsules they consumed. 9 The study was a 2 × 2 factorial design, participants received vitamins/minerals + DHA, DHA + placebo, vitamins/minerals +
placebo, or placebo + placebo; the multi vitamin mineral supplement contained vitamins A (800 mg), B1 (1.4 mg), B2 (1.75 mg), B6 (2 mg), B12 (2.5 mg), biotin (62.5 mg), folic acid (200 mg),
niacin (20 mg), C (100 mg), D (5 mg), E (15 mg), K (30 mg), pantothenic acid (7.5 mg), calcium (162 mg), phosphorus (125 mg), magnesium (100 mg), potassium (40 mg), chloride (36.3 mg). iron
(5 mg), iodine (100 mg), copper (500 mg), manganese (2 mg), chromium (40 mg), molybdenum (50 mg), selenium (30 mg), zinc (5 mg) and lutein (500 mg). 10 The study was a 2 × 2 factorial
design, participants received high micronutrient + high n-3 fatty acid treatment, low micronutrient + high n-3 fatty acid treatment, high micronutrient + low n-3 fatty acid treatment or low
micronutrient + low n-3 fatty acid treatment. All participants additionally received a fruit flavoured biscuit with a creamy filling and a flavoured milk powder drink providing 420 kcal and
13.5 g protein 9.3 g fat (3.7 g n-6 fatty acids), and 3.6 mg vitamin E per day. 11 Recalculated, participants received 100 mg DHA six days a week. 12 Recalculated participants received 930 mg
ALA six days a week. 13 High micronutrient per day: vitamin A 428.6 µg RE, riboflavin 0.77 mg, vitamin B6 0.86 mg, vitamin B12 1.54 µg, folate 257.1 µg, vitamin C 194.7 mg, calcium 198 mg,
iodine 85.7 µg, iron 15.4 mg, zinc 9 mg. Low micronutrient per day: vitamin A 64.3µg RE, riboflavin 0.12 mg, vitamin B6 0.13 mg, vitamin B12 0.23 µg, folate 38.6µg, vitamin C 4.5 mg, calcium
90 mg, iodine 12.9 µg, iron 2.3 mg, zinc 1.5 mg. 14 Recalculated participants received 140 mg ALA per day, six days a week. 15 The study was a 2 × 2 factorial design, participants received
mix of micronutrients, n-3 fatty acids, both or none; the intervention product were added to a base powder that contained 8 g of protein, 12 g sugar and 4 g maltodextrin, additionally in
Indonesia participants received three biscuit providing 100 kcal. 16 Children in Indonesia received the intervention product six days a week, recalculated per day: 75.4 mg DHA, 18.86 mg
EPA. 17 Multivitamin contained: Iron 10 mg, Zinc sulfate 5 mg, vitamin A as retinol acetate 400µg RE, folate 150 µg, vitamin B6 1 mg, vitamin B12 1.5 µg, vitamin C 45 mg, children in Indonesia
received the intervention product six days a week, recalculated per day: Iron 8.6 mg, Zinc sulfate 4.3 mg, vitamin A as retinol acetate 342.9 µg RE, folate 128.6 µg, vitamin B6 0.86 mg, vitamin
B12 1.29 µg, vitamin C 38.6 mg. 18 Only two out of 408 participants were three years old, it was therefore decided to include this study despite inclusion criteria.
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Table 2. Overview of studies supplementing children and adolescents with a disease or disorder with LCPUFA and including a cognitive measure as outcome measure.
Author, n,
Reference
Mean Age in
Years (Sd) and
Any Specifics
DHA, EPA
Dosage per Day
Active Group
Other Constituents Active as
Specified in Manuscript
Placebo as Specified in
Manuscript
Duration
(in Weeks) Cognitive Measure Adherence Effect on Cognition?
Bos
n 79
[48]
ADHD: 10.3
Typically
developing: 10.9
650 mg DHA,
650 mg EPA
70 mg ALA, 30 mg AA, 1 g LA,
2.66 g saturated FA, 2.08 g
MUFA, 6.4 mg vitamin E
60 mg ALA, 1 g LA, 2.59 g
saturated FA, 4.32 g MUFA,
0.52 mg vitamin E
16 Go-No Go task ADHD: 92.2%TD: 91.4% N
Cornu
n 162
[49]
A: 10.2
P: 9.7
ADHD
84 mg-168 mg
DHA, 336–672 mg
EPA1
100µg vitamin A, 1.25 µg
vitamin D, 3.5 mg vitamin E
Olive oil + marine lipid
concentrate containing
4.83 mg EPA + DHA, 100µg
vitamin A, 1.25µg vitamin D,
3.5 mg vitamin E
12
KiTAP (6–10 yr) and TAP
(11–15 yr): Distractibility,
Flexibility and Go/NoGo
OS N
Crippa
n 50
[50]
7–14
ADHD
drug-naïve
500 mg DHA wheat germ oil, lowconcentration vitamin E. 24
Abbreviated ANT: Focused
Attention 4 letters, Shifting
Attentional Set-Visual and
Sustained Attention.
83.2%
Y, DHA group showed a
decrease in misses in Focused
Attention 4 letters task at 6 mo,
placebo group showed decrease
at 4 mo but not at 6 mo. DHA
group showed reduction in false
alarms irrelevant target in
Focused Attention 4-letters task
at 6 mo.
Demmelmair
n 109
[51]
5–13
PKU
Between 20 and
254 mg DHA2
14:0 5–64 mg, 14:1 0–1 mg, 16:0
37–61 mg, 16:1 1.5–14 mg 18:0
15.5–20 mg, 18:1 403–536 mg,
18:2 n-6 29–35, 18:n3–3
0.5–1 mg, 20:0 1.5–2 mg, 20:1
n-9 1–2 mg, 22:0 3.5–5 mg, 24:1
n-9 1–2 mg, 22:5 n-3 0–3 mg3
16:0 16.5–33 mg, 16.1
0.5–1 mg, 18:0 16–32 mg, 18:1
428.5–857 mg, 18:2 n-6
29–58 mg, 18:3 n-3 0.5–1 mg,
20:0 1.5–3 mg, 20:1 n-9
1.5–3 mg, 22:0 4–8 mg, 24:1
n-9 1.5–3 mg4
24 Raven Progressive Matrices(standard or coloured) 96–102% N
Hirayama
n 40
[52]
6–12
ADHD
514 mg DHA,
100 mg EPA5 - Olive oil 16
Adapted Test of Visual
Perception, Visual and
Auditory Short-Term
Memory, Developmental
Test of Visual–Motor
Integration, Continuous
Performance Test
NR
Y, Visual Short Term Memory
and number of errors of
commission on Continuous
Performance Test improved sig.
in control group.
Kean
n 112
[53]
6–14, mean 8.7
ADHD rating
score >15
16.5–22 mg DHA,
21.9–29.2 mg
EPA 6
300–400 mg olive oil,
0.68–0.90 mg vitamin E,
diverse sterol esters (amounts
not specified)
Olive oil, lecithin, coconut oil
and beta-carotene 14
COMPASS cognitive battery:
Word Presentation,
Immediate Word Recall,
Picture Presentation, Simple
Reaction Time, Choice
Reaction Time, Numeric
Working Memory, Delayed
Word Recall, Delayed Word
Recognition, Delayed
Picture Recognition. TOVA
96.7%
Y, improved memory accuracy
score in active group for
recalled target and non-target
pictures correctly and sig.
overall picture recognition
accuracy only at 8 weeks not at
14 weeks. No sig. differences in
TOVA. Additionally subgroup
differences showed difference
between diagnosed and
non-diagnosed participants in
response to supplement.
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Table 2. Cont.
Author, n,
Reference
Mean Age in
Years (Sd) and
Any Specifics
DHA, EPA
Dosage per Day
Active Group
Other Constituents Active as
Specified in Manuscript
Placebo as Specified in
Manuscript
Duration
(in Weeks) Cognitive Measure Adherence Effect on Cognition?
Rodriguez
n 95
[54]
6–19
ADHD
1000–2000 mg
DHA, 90–180 mg
EPA 7
150–300 mg n-3 DPA, 4.5–9 mg
vitamin E Olive oil 24
AULA Nesplora test, d2 test
of attention OS N
Sinn
n 167
[55]
7–12
ADHD symptoms
no stimulant
medication
174 mg DHA,
558 mg EPA 8
60 mg GLA, 10.8 mg vitamin E,
multivitamin 9
Palm oil: 44.3% palmitic acid
C16, 4.6% stearic acid C18,
1% myristic acid C14, 38.7%
oleic acid C18, and 10.5% LA
15w–one
way CO
15w
Digit-Symbol Coding,
Inspection Time, Rey
Auditory-Verbal Learning
Test, Creature Counting,
DSB, Knock and Tap, Stroop
Colour-Word Test.
OS
Y, PUFA group had sig
improvement compared to
placebo on Creature Counting
with large effect.
Stevens
n 50
[56]
P: 10.1
A: 9.5
ADHD + high
thirst/ skin
symptom score
480 mg DHA,
80 mg EPA
40 mg AA, 96 mg GLA, 24 mg
vitamin E Olive oil 16
Conners’ Continuous
Performance Test,
Woodcock-Johnson
Psycho-Educational
Battery-Revised
88%
Y, hit reaction time on Conner’s
Continuous Performance Test
showed a treatment effect in
favor of treatment group.
Auditory processing showed
improvement in treatment
group only (no significant
difference between groups).
Vaisman
n 83
[57]
8–13
ADHD and
impaired visual
sustained
attention
performance
FO: 96 mg DHA,
153 mg EPA or n-3
LCPUFA
containing PLs:
95 mg DHA,
156 mg EPA
FO: 14:0 63 mg, 16:0 147 mg,
18:0 31 mg, 20:0 2 mg, 22:0
2 mg, 24:0 4 mg, 16:1 n-7 68 mg,
18:1 n-9 95 mg, 18:1 n-7 25 mg,
20:1 n-9 12 mg, 22:1 n-9 7 mg,
18:2 n-6 18 mg, 18:3 n-6 2 mg,
20:4 n-6 7 mg, 18:3 n-3 25 mg
LC-PUFA
containing PLs: 14:0 19 mg,
16:0 141 mg, 18:0 7 mg, 22:0
1 mg, 16:1 n-7 19 mg, 18:1 n-9
37 mg, 18:1 n-7 44 mg, 20:1 n-9
5 mg, 22:1 n-9 5 mg, 18:2 n-6
11 mg, 18:3 n-6 1 mg,
20:4 n-6 4 mg, 18:3 n-3 7 mg,
22:5 n-3: 4 mg 10
16:0 30 mg, 18:0 13 mg, 20:0
5 mg, 22:0 3 mg, 24:0 1 mg,
16:1 n-7 1 mg, 18:1 n-9
415 mg, 20:1 n-9 12 mg, 22:1
n-9 4 mg, 18:2 n-6 150 mg,
18:3 n-3 69 mg
12 TOVA OS
Y, The PL-n3 and, to a limited
extent, the FO treatment
significantly improved errors of
commission, response time,
and response time variability as
compared with
placebo intervention
Voigt
n 63
[58]
6–12
ADHD 345 mg DHA - Not specified 16
TOVA, The Children’s Color
Trails test OS N
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Table 2. Cont.
Author, n,
Reference
Mean Age in
Years (Sd) and
Any Specifics
DHA, EPA
Dosage per Day
Active Group
Other Constituents Active as
Specified in Manuscript
Placebo as Specified in
Manuscript
Duration
(in Weeks) Cognitive Measure Adherence Effect on Cognition?
Widdenhorn-
Muller
n 110
[59]
6–12
ADHD
120 mg DHA,
600 mg EPA 15 mg vitamin E Olive oil 16
DSF, DSB, Letter Number
Sequencing, HAWIK
Number-Symbol, Symbol
Search Test, KITAP or TAP
(dependent on
age participant)
OS
Y, sig. improvement on working
memory index score, Digit Span
subtest and DSB.
A = active, AA = arachidonic acid, ADHD = attention deficit hyperactivity disorder, CO = cross over, COMPASS = computerized mental performance assessment system, DHA =
docosahexaenoic acid, DSB = digit span backwards, DSF = digit span forwards, EPA = eicosapentaenoic acid, FA = fatty acids, FO = fish oil, HVLT = Hopkins Verbal Learning test, KITAP
= “TestBatterie zur Aufmerksamkeitsprüfung für Kinder”, LCPUFA = long-chain polyunsaturated fatty acids, MVM = multivitamins/minerals, N = no, NR = not reported, OS = otherwise
specified, P = placebo, PKU = phenylketonuria, PLs = phospholipids, RT = reaction time, MFFT = Matching Familiar Figures Task, TAP = “Testbatterie zur Aufmerksamkeitsprüfung”,
MUFA = monounsaturated fatty acids, TOVA = Test of Variables of Attention, TD = typically developing, Y = yes. • Note that in some studies also other measures were included such as
academic achievement tests (spelling, reading, math), mood measures and more, these are not reported here 1 Dosages depended on age 6–8 yr 336 mg EPA and 84 mg DHA, 9–11 yr
504 mg EPA, 126 mg DHA, 12–15 yr 672 mg EPA, 168 mg DHA. 2 There were five different capsules (0, 20, b3,80 or 127 mg DHA per capsule) and participants <35 kg consumed one capsule
per day, those >35 kg consumed two capsules per day. 3 The values reported here are the amount of fatty acids for the lowest DHA dose and the highest DHA dose. 4 Values reported are
for the low and high placebo dose. 5 Recalculated 3600 mg DHA, 700 mg EPA per week 6 Participants <45 kg received three capsules per day, participants >45 kg received four capsules per
day, note that PCSO-524 extract of the New-Zealand green-lipped mussel was used. 7 Participants <32 kg received one sachet per day, participants >32 kg received two sachets per day. 8
There were three study groups: PUFA, PUFA + multivitamins/minerals and placebo. 9 Multivitamin/mineral supplement contained: vitamin A 175 IU, thiamine nitrate 700 mcg, vitamin B2
1.1 mg; vitamin B6 1.3 mg, nicotinamide 12 mg, vitamin C 60 mg, vitamin D3 100 IU, vitamin B12 1.5 mcg, vitamin E6 IU, biotin 50 mcg, vitamin B5 2.7 mg, folic acid 100 mcg, calcium
hydrogen phosphate anhydrous 33.9 mg, ferrous fumarate 7.5 mg, magnesium oxide 8.32 mg, manganese sulphate 77 mcg, zinc oxide 1.25 mg, copper gluconate 178.6 mcg, and potassium
iodide 118 mcg 10 LC-PUFA containing PLs supplement also contained phospholipids: 300 mg phosphatidylserine, 66 mg phosphatidylethanolamine, 48 mg phosphatidic acid, 24 mg
lysophospholipids, 18 mg phosphatidylcholine, 12 mg phosphatidylinositol.
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3.2. Omega-3 Index Equivalence
Of the 33 studies included in this review, 13 studies had no reported blood fatty acid
concentrations [29,31,33,35,36,38,43–45,49,52,53,55]. In 20 studies, fatty acid concentrations were
reported, and the fatty acid concentrations were analyzed in a variety of bodily tissues and blood
fractions (note that in some studies multiple fractions were utilized): plasma fatty acids [27,32,33,56],
phospholipids in erythrocyte membranes [28,41], plasma phosphatidylcholine [30], erythrocyte
phosphatidylcholine [30], erythrocyte phosphatidylethanolamine [30], cheek cells [37,48], capillary whole
blood [40,46,47,50], serum phospholipids [42,57,58], total fatty acids in erythrocyte membrane [39,56,59],
glycerol-phospholipids in plasma [51] and erythrocytes [54]. Unfortunately, recalculation formulae to
the O3I equivalence are only available for a limited number of blood fractions [60]. The recalculation
to the O3I equivalence was thus not possible for seven studies because they used a blood fraction
for which no recalculation formula is available: erythrocyte and plasma phosphatidylcholine [30],
erythrocyte phosphatidylethanolamine [30], cheek cells [37], serum phospholipids [42], cheek cells [48],
glycerol-phospholipids in plasma [51] or serum phospholipids [57,58]. Moreover, in three studies only
DHA levels were reported and recalculation to the O3I equivalence was thus not possible [39,40,54].
Lastly, one study only reported the baseline fatty acid blood levels [50]. Therefore recalculation to the
O3I equivalence was possible for nine out of the 20 studies in which fatty acid values were reported
(see Table 3 and Figure 2; Note that Jackson et al. is reported twice in the figure as their study included
an EPA-arm and a DHA-arm).
Figure 2. Omega-3 index equivalence at start and end of study for active and placebo group for studies
in which blood was collected and recalculation to the Omega-3 index equivalence was possible. Studies
in which a positive effect of supplementation was shown are indicated with an *. Note that Jackson et al.
are in the figure twice as their study included an eicosapentaenoic acid (EPA) arm and a docosahexaenoic
acid (DHA) arm. FO = fish oil.
When looking at the nine studies that allowed for recalculation to the O3I equivalence, the increase
in the O3I equivalence in the active group varied between 0.87% and 4.75% (see Table 3). Four of the
nine studies showed a positive significant effect of supplementation on at least one cognitive measure
in the main analyses in the overall sample.
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Table 3. Recalculation of measured blood fractions in included studies to Omega-3 Index equivalence.
O3I Equivalence Before O3I Equivalence After O3I Equivalence Change Significant Effecton Cognition?
DHA, EPA Dose per Day Blood Fraction Formulae Used 1 Intervention Placebo Intervention Placebo Intervention Placebo
Typically developing
Antypa [27] 250 mg DHA,1740 mg EPA Plasma FA 0.94 x + 1.17 3.46 3.18 6.28 3.36 2.82 0.18 Y
Baumgartner 2 [28] 240 mg DHA, 46 mg EPA
Total PP fraction
of erythr
membranes
3.20 a
3.17 b
3.22 c
3.24 d
6.27 a
6.33 b
4.03 c
3.97 d
3.07
3.16
0.81
0.73 N
Jackson 3 [33]
DHA rich group: 450 mg
DHA, 90 mg EPA
EPA rich group: 300 mg
EPA, 200 mg DHA
Serum FA 0.94 x + 1.17 3.34
e
3.31 f 3.16
4.21 e
4.24 f 3.29
0.87
0.93 0.13 Y
Muthayya [41] 86 mg DHA
Erythr
membranes in
PP fraction
- 3.373.38
3.37
3.48
5.55
5.59
3.85
3.86
2.18
2.21
0.48
0.38 N
Hamazaki [32] 1500–1800 mg DHA,200–240 mg EPA4 Total serum FA 0.94 x + 1.17 4.93 5.96 9.25 5.68 4.32 −0.28 N
Ryan [46] 400 mg DHA Capillary WB 1.10 x + 0.65 2.08 2.08 4.83 2.19 2.75 0.11 N
Van der Wurff [47] 280 mg DHA,520 mg EPA Capillary WB - 3.72 3.83 4.86 3.98 1.03 0.15 N
With disorder/disease
Stevens [56] 480 mg DHA, 80 mg EPA Eryth membranes - 4.08 3.78 8.83 3.53 4.75 −0.25 Y
Widdenhorn-Muller [59] 120 mg DHA,600 mg EPA Eryth membranes - 4.13 4.05 7.82 4.03 3.69 −0.02 Y
DHA = docosahexaenoic acid, EPA = eicosapentaenoic acid, erythr = erythrocytes, FA = fatty acids, n = no, O3I = Omega-3 Index, PP = phospholipids, y = yes, WB = whole blood. 1 For
some blood fraction no conversion formulae is needed these are indicated with a -. 2 In the study of Baumgartner a 2 × 2 design was utilized the data presented here are for: placebo +
DHA/EPAa, iron + DHA/EPA b, iron+ placeboc, placebo + placebod. 3 In the study of Jackson et al. two kinds of n-3 LCPUFA supplementation were utilized, the data presented here are
for: DHA-rich fish oile, EPA-rich fish oilf .4 Supplementation dose was dependent on body weight.
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Figure 2 shows that in three [27,56,59] of those four studies [27,33,56,59] in which a positive
effect on cognition was shown, an increase in O3I equivalence was achieved and the O3I equivalence
after the intervention was higher than >6% in the active group. There were two studies with an O3I
equivalence >6% after supplementation in the active group, however, there were no significant effects
of supplementation on cognitive measures [28,32]. The notion that an increase in O3I equivalence
is related to improved cognition, is supported by the fact that six [30,37,39,46,57,59] out of the 10
studies [30,37,39,46,47,51,56–59] that related blood values to cognitive outcomes showed significant
positive associations or correlations between (change in) DHA and/or EPA blood values and cognitive
tests used.
3.3. Supplementation Dose
The supplementation dosage of DHA and EPA varied immensely in the 33 included studies,
varying from 16.5 mg to 3600 mg DHA per day, and from 0 mg to 1740 mg EPA per day. Supplementation
could either contain only DHA or DHA in combination with EPA. Of the 15 studies [27,31–40,43–45,47]
in which participants received supplementation of ≥450 mg DHA + EPA per day, 8 (i.e., 53%) showed a
positive effect [27,31,33,34,38,43–45] (see Figure 3; note that Jackson a and b, Kennedy, and McNamara
are represented twice as they included two supplementation groups). In contrast, in only two of the
eight studies with a lower supplementation dosage (i.e., <450 mg DHA + EPA per day) a significant
effect was shown [29,30]. Moreover, note that in one of those two studies the effect was in favor of the
placebo group [29]. While in in six of the eight studies with a daily dosage of <450 mg DHA + EPA per
day no significant effects on cognition were shown [28,36,39,41,42,46].
Figure 3. n-3 long-chain polyunsaturated fatty acids (LCPUFA) supplementation studies that studied
cognition in typically developing children. Studies indicated with a * are those studies in which positive
effects of supplementation on cognition are reported. Dotted line indicates supplementation of 450 mg
docosahexaenoic acid (DHA) + eicosapentaenoic acid (EPA)per day. Note that in the study of Hamazaki et al.
dose differed based on bodyweight. The dose noted here is the lowest dose. Note that Jackson, Kennedy
and McNamara included two n-3 LCPUFA dose groups, these are reported separately here.
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3.4. Children and Adolescents with a Disease or Disorder
Of the 12 studies in which the effect of n-3 LCPUFA supplementation on cognition in children and
adolescents with a disease or disorder was investigated (see Table 2, note that the study of Vaisman et al.
included two n-3 LCPUFA dose groups (fish oil (FO) and n-3 LCPUFA containing phospholipids (PLs)),
these are reported separately in the table), six showed a positive effect on cognition in favor of the
n-3 LCPUFA supplementation group [50,53,55–57,59]. However, in contrast, one study favored the
placebo group [52]. In contrast to the studies in which typically developing children and adolescents
were investigated, there appeared to be no clear cut-off point above which a positive effect of DHA/EPA
supplementation on cognition was shown (see Figure 4).
Figure 4. n-3 long-chain polyunsaturated fatty acids (LCPUFA) supplementation studies that studied
cognition in children and adolescents with a disease or disorder. Studies indicated with a * are
those studies in which positive effects of supplementation are reported. Note that in the study of
Demmelmair et al. and Cornu et al., dose differed based on bodyweight—the dose noted here is the
lowest dose. Note that the study of Vaisman et al. included two n-3 LCPUFA dose groups (fish oil (FO)
and n-3 LCPUFA containing phospholipids (PLs)), these are reported separately here.
4. Discussion
The goal of the current review was to investigate what O3I is needed to improve cognition and
whether the dose of DHA/EPA plays a role in the effect of n-3 LCPUFA supplementation on cognition.
There seems to be some evidence that significant cognitive effects of n-3 LCPUFA supplementation
can only be shown when the post-intervention O3I is increased and reaches at least 6%. However,
due to the limited number of studies for which recalculation of the O3I equivalence was possible, this
result should be considered with caution. Additionally, there seems to be some evidence that a dosage
≥450 mg DHA + EPA per day does lead to improved cognition in typically developing children and
adolescents. For children and adolescents with a disease or disorder, no clear dosage cut-off could
be determined.
4.1. Omega-3 Index Equivalence
We showed that significant cognitive effects of n-3 LCPUFA supplementation can only be shown
when the post-intervention O3I is increased and reaches at least 6%. There was only one study in
which only a minor increase in O3I equivalence was shown (i.e., the increase in O3I equivalence was
0.87%) and a relatively low O3I equivalence at the end of the intervention for the active group was
achieved, but still a positive significant effect on cognition was shown [33]. In this study, both a positive
effect of DHA rich supplementation on cognition and a negative effect for both the DHA and EPA rich
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supplementation was shown. However, in this study, 15 different cognitive tests with a total of 29
outcome measures were reported, without correction for multiple testing. The significant effects could
thus reasonably be ascribed to a type I error and should be interpreted with caution. Two studies did
have an O3I equivalence >6% after n-3 LCPUFA supplementation, but did not show a positive effect
on cognitive measures [28,32]. The children in the study of Baumgartner et al. were iron deficient and
often undernourished [28], both factors which can negatively influence cognitive performance [61–63],
and thus mask a potential beneficial effect of the n-3 LCPUFA supplementation. The students in the
study of Hamazaki et al. had already a rather high O3I equivalence (i.e., O3I equivalence of 5.68% in
active group and 5.96% in placebo group) at the start of the study, which makes it less likely to be able
to show any effect of supplementation due to a ceiling effect [32].
It has also been suggested that an overlap in O3I between placebo and treatment group could cause
non-significant treatment effects [64], especially as most authors analyze their results not according
to blood values, but according to intention to treat. In this light it is interesting that in the study
of Montgomery et al., a significant difference between active and placebo group was shown post
intervention for both digit span forward and backward, but change scores in both digit span tests
did not differ significantly [40]. It might not be surprising that the change scores did not differ when
we consider that there was a clear overlap in DHA blood values between the placebo group and the
active group. A similar problem arose in the study of van der Wurff et al., a similar Omega-3 index
post-intervention was measured in the placebo and the active group due to non-adherence to the study
protocol, which could explain the result of similar cognitive test results in both groups [47].
The fact that an O3I >6% is possibly related to improved cognitive measures is in line with the
results found for cardiovascular health and mental health. As mentioned previously, for cardiovascular
health, an O3I of >8% was related to the highest cardio-protection, while an O3I < 4% was related
to the lowest cardio-protection [21]. Additionally, there are some studies that have shown a positive
relationship between increase in n-3 LCPUFA blood levels and less depressive symptoms [65,66].
Therefore, it seems likely that to show positive effects of n-3 LCPUFA supplementation, a sufficient n-3
LCPUFA level in the body should be achieved, which appears to be an O3I of more than 6% for cognition.
It is important to note that many of the studies investigating the effect of n-3 LCPUFA supplementation
on cognition included in this review did not include measurements of n-3 LCPUFA levels in the body.
Additionally, recalculation formulae to the O3I equivalence are not available for all blood fractions.
If future n-3 LCPUFA supplementation studies include blood levels, as suggested by the International
Society for the Study of Fatty Acids [67], possibly a more precise target range for cognitive functioning
can be determined, similar to the one available for cardiovascular health. Additionally, considering the
large interpersonal difference in response to LCPUFA supplementation [64,68], it seems prudent that
future studies utilize a personalized LCPUFA supplementation dose approach.
4.2. Supplementation Dose in Typically Developing Children and Adolescents
The results of the current review point to some evidence that a dose above 450 mg DHA + EPA
per day does lead to improved cognition in typically developing children and adolescents. Fifty-three
percent of the studies in which children and adolescents received ≥450 mg DHA + EPA showed a
positive effect on cognition. However, do note that one of those positive studies was the study of
Jackson et al., in which both positive and negative effects of supplementation were shown, also note
that these results could be due to a type I error as already mentioned previously [33].
There were six studies with a daily dose ≥450 mg DHA + EPA in which no significant positive
effects were shown [32,35–37,39,40,47]. One of these studies did show significant effects/associations
in secondary analyses, Kirby and colleagues showed significant effects of supplementation on visual
attention and impulsivity in those that were compliant with the protocol, while the primary intent to
threat analyses did not show significant results [37]. For the other five studies, it is unclear as to why
these studies did not show an effect, there was, for example, no clear relationship with supplementation
duration or sample size.
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Of the studies with a daily supplementation dose of ≥450 mg DHA + EPA that did show a
significant effect, two had a duration of four weeks, one of eight weeks, four of 12 weeks, one of
16 weeks and one of 28.6 weeks. Of the studies with a daily supplementation dose of ≥450 mg DHA +
EPA that did not show a significant effect, one had a duration of four weeks, one of eight weeks, one of
12 weeks, two of 16 weeks and one of 52 weeks. Moreover, looking at sample size, no clear relationship
could be seen; the sample sizes of the studies ≥450 mg of DHA + EPA that did show a significant effect
varied from 34 to 408 participants, while the sample sizes of studies that did not show a significant
effect varied from 41 to 376.
One of the two studies that did show a significant effect even though they supplemented with
<450 mg DHA + EPA was the study of Dalton et al., in which fish flour was used as supplementation
source [30]. Fish flour also includes other nutrients (e.g., protein) which could, especially for the
undernourished children included in the study of Dalton et al., provide additional cognitive benefits,
which could also explain the significant cognitive findings. The second study with a dose below 450 mg
that showed a significant effect was the study of Benton et al. [29]. In this study, it was shown that
those taking a DHA supplement for 50 days forgot more words at the end of the study on a word
recall test than those that took the placebo. However, this significant effect was not shown in the
other memory test which they utilized, the capital recall test. Additionally, from the graphs in the
manuscript of Benton et al., it can be deducted that the DHA group already made more mistakes at
baseline (it is unclear whether this difference is significant) and that the difference between the DHA
and placebo group was rather small (i.e., less than one word). It thus seems unlikely that this indicates
an actual negative effect of DHA supplementation on memory performance.
Note that in the study of Kennedy et al., a significant effect of supplementation was shown for the
low dose group of 400 mg DHA + 4 mg EPA per day, but not for the high dose group 1000 mg DHA
+ 20 mg EPA [36]. After eight weeks of supplementation the children in the low dose group had a
significantly higher speed on the Word Recognition test in comparison to the children in the placebo
group, while the children in the high dose group had a significantly slower reaction time than the
placebo group. For the low dose group this was the case in both the pre- and the post-breakfast session
and in the high dose group only in the post-breakfast session. However, as the authors themselves
note, the results are inconsistent, it was the only significant effect among 25 cognitive measures (i.e.,
likely a type I error), the effects were not found on other memory tests, nor on the same task from a
different test battery (i.e., the researchers utilized two test batteries). Considering the inconsistent
findings and the limitations mentioned above, we classified this study as not-significant. Overall,
there is evidence that a dosage above 450 mg DHA + EPA per day does lead to improved cognition in
typically developing children and adolescents.
The finding regarding the positive effects of ≥450 mg DHA + EPA per day for cognition is in line
with the earlier review of Emery et al. [23], showing that when studies with a dose of less than 400 mg
DHA + EPA were excluded, a small effect size on the domains of recall and recognition long-term
memory (i.e., the ability to recognize items after an extended time period) was shown, while this
was not the case when studies with a dose <400 mg were included. It is, however, important to note
that Emery et al. did not include all studies which were included in this review (i.e., 33 studies were
included in the current review of which 16 were also included in Emery et al.). Additionally Emery et al.
included studies of children aged 0–4 years, cross-over designs and studies that used foods as form of
n-3 LPCUFA supplementation (i.e., fish) which were not included in this current review. However,
despite the differences in studies included in the review of Emery et al. and this review the conclusion
of at least 400 mg and 450 mg of n-3 LCPUFA per day are comparable. Furthermore, the current
review has additionally shown that an increase in O3 I equivalence and an O3I equivalence >6% makes
it more likely to show positive effects of supplementation on cognition in children and adolescents.
This finding again points to the importance of including blood values in LCPUFA supplementation
trials [67].
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The finding from the current study is also in line with the findings for cardiovascular health.
Meyer et al. showed that supplementation dosages of >500mg DHA per day lead to cardio-protective
effects, but not doses <500 mg per day [20]. The brain can only incorporate about 4 mg DHA per
day [69] and only 0.5% of circulating DHA is delivered to the central nervous system [69]. Therefore,
to achieve a level of incorporation of 4 mg per day, a relatively high intake of DHA is needed and
positive effects of DHA supplementation will only be present with higher doses of supplementation.
4.3. Supplementation Dose in Children and Adolescents with a Disease or Disorder
In contrast to the results for typically developing children and adolescents, we were not able
to show a clear cut-off for a daily dose of DHA + EPA above which a positive effect on cognition
could be shown in children and adolescents with a disease or disorder, although in half of studies (i.e.,
6/12 studies) a positive effect was shown. The fact that we could not show a cut-off dose for children
with a disease or disorder is surprising, as it has been suggested that n-3 LCPUFA supplementation
might be more beneficial for those who are underperforming on cognitive and academic measures [45],
such as children with ADHD. Note that the vast majority of studies (i.e., 11/12 studies) in children
and adolescents with a disease or disorder included in the current review focused on children and
adolescents with ADHD. Therefore, this discussion focuses on ADHD. Children with ADHD are known
to have impaired executive functions such as inhibition and attention, cognitive functions which are
primarily located in the frontal cortex, a brain region especially rich in DHA [70]. However, as ADHD
is a multifactorial disorder with a complex etiology, it might be the case that not for all subgroups of
children with ADHD a beneficial effect of n-3 LCPUFA supplementation could be expected. Lastly,
it has been suggested that children with ADHD have lower n-3 LCPUFA levels in their body [71]
and higher levels of inflammation [72]. It might be that the dose of DHA/EPA utilized in the studies
included in this current review were too low. It is important to note that recalculation to the O3I
equivalence was only possible for two studies, both of which did show positive effects, and both also
had a rather high O3I equivalence in the active group at the end of the intervention (>6%). More
research with blood assessments, making recalculation to the O3I equivalence possible, is warranted in
children/adolescents with a disease or disorder.
4.4. Strengths and Limitations
The strength of this review is the fact that it is the first review in which the relationship between
O3I equivalence and cognitive outcomes in children and adolescents is investigated.
However, this review had a number of limitations. Like many previous reviews, we have to
conclude that there is large variability in the studies included in this review. The studies differed on
various factors: the study population (i.e., age, nutritional status); composition of supplements (i.e.,
EPA/DHA ratio, but also inclusion of other fatty acids or nutrients); and duration of supplementation.
For the assessment of cognition, a wide variety of cognitive tests were used, often with multiple subtests,
assessing all different aspects of cognition. Additionally, the number of cognitive measures used varied
from one to 25. In the studies with multiple tests, chance findings might be a problem. Moreover,
in many studies, blood levels were not assessed or not reported in such a way that recalculation
to the O3I equivalence was possible; either a blood fraction for which no recalculation formulae is
available was used or the DHA and EPA values were not both reported before and after the intervention.
Therefore, only nine out of 33 studies could be compared on the O3I equivalence, which limits the ability
to draw conclusions. However, in some studies for which we could not calculate an O3I equivalence,
but where blood values were available, the authors executed analyses examining the relationship
between blood values and cognitive test outcomes. These analyses relating blood values to cognitive
test outcome support our finding: six out of the 10 studies in which those analyses were executed
showed significant positive associations or correlations between (change in) DHA and/or EPA blood
values and cognitive tests used. Additionally, recently, some controversy regarding the link between
the O3I and brain omega-3 level has arisen. In some animal studies, a positive relationships between
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increases in omega-3 fatty acids in erythrocytes and brain DHA level has been shown [73,74], while
in other studies, the correlation between erythrocyte O3I and brain O3I was negative [75]. Whether
erythrocyte O3I is related to brain O3I in humans thus remains unsettled. We did not take the source
of omega-3 fatty acid supplementation in consideration (i.e., phospholipids, ethyl esters, krill oil, etc.),
while some authors have suggested that phospholipids are more efficient in increasing brain levels
than other sources of DHA. This could considered to be a limitation, however the notion that different
sources of omega-3 fatty acids have different levels of effectiveness in increasing DHA (brain) levels
has never been proven conclusively [68]. Due to the large variability in the cognitive tests used, we did
not take into consideration what cognitive test was used, which might be considered a limitation of this
review. However, combining different cognitive tests into one measure is also not without problems as,
even if the tests have a similar underlying construct, the actual construct might be minimally different
and operational differences occur, which leads to problems with the comparison of test results [24].
5. Conclusions
An increase in the O3I > 6% and daily supplementation of ≥450 mg DHA + EPA makes it more
likely to show positive effects of supplementation on cognition in children and adolescents. However,
more research is needed where the O3I is measured, to be able to determine a more precise O3I target
range for the positive effects on cognitive functioning.
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Appendix A
Table A1. Search Strategies.
PUBMED
Search Strategy
(((“fatty acid”[Title/Abstract]) OR “fatty acids”[Title/Abstract]) OR “omega-3”[Title/Abstract])
OR “omega-6”[Title/Abstract]) OR pufa[Title/Abstract]) OR lcpufa[Title/Abstract]) OR
mufa[Title/Abstract]) OR fish oil*[Title/Abstract]))) AND ((child [Title/Abstract] OR children
[Title/Abstract] OR childhood [Title/Abstract] OR kid [Title/Abstract] or kids [Title/Abstract] OR
girl* [Title/Abstract] OR boy* [Title/Abstract] OR teenage* [Title/Abstract] OR youth*
[Title/Abstract] OR youngster* [Title/Abstract] OR preschool* [Title/Abstract] OR pre-school*
[Title/Abstract] OR kindergarten* [Title/Abstract] OR “elementary school” [Title/Abstract] OR
elementary-school [Title/Abstract] OR juvenile* [Title/Abstract] OR minors [Title/Abstract] OR
minor [Title/Abstract] OR pediatric* [Title/Abstract] OR paediatric* [Title/Abstract] OR
schoolchild*[Title/Abstract] OR toddler*[Title/Abstract] OR teen [Title/Abstract] OR teens
[Title/Abstract] OR child, preschool [MeSH terms] OR child [MeSH terms])) AND
(cognit*)Searched 03–07-2019–421 hits
Web of Science
Search Strategy
#1
(TS = (“fatty acid” OR “fatty acids” OR “omega-3” OR “omega-6” or pufa OR lcpufa OR
mufa OR “fish oil*”))
Indexes = SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan = All years
#2
(TS = (child OR children OR childhood OR kid OR kids OR girl* OR boy* OR teenage*
OR youth* OR youngster* OR preschool* OR pre-school* OR kindergarten* OR
“elementary school” OR elementary-school OR juvenile* OR minors OR minor OR
childhood OR pediatric* OR paediatric* OR schoolchild OR toddler* OR teen OR teens))
Indexes = SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan = All years
#3
(TS = (cognit*))
Indexes = SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan = All years
#3 AND #2 AND #1
Indexes = SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan = All years
Searched 03-07-2019-469 hits
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